Mitiglinide: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus

Phillippe, Haley M.; Wargo, Kurt A.

doi:10.1345/aph.1p136

Cited by 21 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, however, no studies have confirmed the effects of the treatment regimens commonly used in our institution on glucose fluctuations, as measured by CGM, in daily life. Therefore, the objective of this study was to examine the effects of adding sitagliptin (a DPP-4 inhibitor [16,17]) or mitiglinide (a glinide [18,19]) to ongoing acarbose therapy on 72-h daily blood glucose excursions measured by CGM during daily life. CGM was performed during Week 3 of a 4-week treatment period.…”

Section: Introductionmentioning

confidence: 99%

Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study

Osonoi¹,

Saito²,

Tamasawa³

et al. 2014

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study

Osonoi¹,

Saito²,

Tamasawa³

et al. 2014

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Rapid‐onset and short‐acting insulinotropic agents are often used in an early stage of T2DM because they alleviate PBG by rapidly increasing insulin secretion after a meal and less frequently induce hypoglycaemia than SU [4]. Mitiglinide, a benzylsuccinic acid derivative, is a new rapid‐ and short‐acting insulinotropic SUR ligand [5–7]. However, mitiglinide shows selective action on the K ATP channel of pancreatic β ‐cells, and its affinity to Kir 6.2/SUR 1 is higher than that of repaglinide and nateglinide [8].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial

Yan

et al. 2011

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

This study was performed to examine the efficacy and safety of mitiglinide in type 2 diabetes patients (T2DM). Enrolled patients had received treatment with diet and exercise in the previous 3 months with glycosylated haemoglobin (HbA1c) 7-10%, and were randomized to receive mitiglinide (n = 111, 5-20 mg/meal) or nateglinide (n = 114,60-120 mg/meal) for 16 weeks. Primary and secondary efficacy endpoints were assessed by the changes in HbA1c, fasting blood glucose (FBG) and postprandial glucose (PBG) levels. The baseline HbA1c value was 8.2 and 8.3% in both groups. At the end of study, the reduction of HbA1c values from baseline by mitiglinide was slightly more than that by nateglinide (-1.11% vs. -0.76%), but not statically significant (p = 0.06). Final FBG and PBG were comparable for the two treatments. There were 2.8% subjects treated with nateglinide who had hypoglycaemic episodes, but none in the mitiglinide treatment group. The results indicate that mitiglinide and nateglinide had similar effects on FBG, PBG and HbA1c in T2DM patients after the 16-week treatments.

show abstract

“…Meglitinide is a drug aimed at primarily correcting postprandial hyperglycemia to avoid a delay in insulin secretion and the concomitant protraction of the hyperglycemic state and therefore has a relatively short duration of action [33,39]. However, DPP-4 inhibitors exert a hypoglycemic effect through incretin effects that lasts for 24 h [23].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Saxagliptin versus Mitiglinid in patients with type 2 diabetes and end-stage renal disease

Sakai

Sakai²,

Mugishima

et al. 2017

Ren Replace Ther

View full text Add to dashboard Cite

Background: There are very few oral antidiabetic drugs recommended for patients on dialysis. Saxagliptin is known for its potent effect and long duration of action. In this study, we compared the efficacy of Saxagliptin with Mitiglinid for diabetes control and renal anemia in hemodialysis patients with type 2 diabetes mellitus. Methods: We performed a 6-month prospective, open-label, parallel group study of 41 patients with type 2 diabetes mellitus undergoing hemodialysis who took alpha-glucosidase inhibitors or meglitinides and did not use insulin. Saxagliptin and Mitiglinid were administered at 2.5 and 5 mg/day, respectively. The primary outcomes were changes in hemoglobin A1c (HbA1c) and glycated albumin (GA). Other efficacy assessments included changes in Hb, darbepoetin alpha (DA) dose, and erythropoietin responsiveness index (ERI). Results: No patient required an increase in Saxagliptin or Mitiglinid dose, and there were no cases of hypoglycemia with symptoms. HbA1c and GA values were not significantly different between both groups. For HbA1c, the gradient of the regression line of the Saxagliptin and Mitiglinid groups were Y = −7.144e-005*X + 6.023 and Y = −0. 02604*X + 6.292, respectively, and no significant difference was found (p = 0.3281). However, for GA, the regression line of the Saxagliptin group significantly decreased (Y = −0.5036*X + 19.34 and Y = −0.2346*X + 18.79, p = 0.0371). Both groups did not have a significant change in the DA dose through the observation period. However, the DA dose of the Saxagliptin group significantly decreased when we compared the regression lines (Y = −0.8304*X + 21. 06 and Y = 0.6286*X + 16.12, p = 0.0019) of both groups. Furthermore, ERI did not change significantly but showed a significant difference when regression lines were compared (Y = −0.2030*X + 6.654 and Y = 0.1116*X + 5.288, p = 0.0082).

show abstract

Mitiglinide: A Novel Agent for the Treatment of Type 2 Diabetes Mellitus

Cited by 21 publications

References 16 publications

Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study

Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study

Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial

Efficacy of Saxagliptin versus Mitiglinid in patients with type 2 diabetes and end-stage renal disease

Contact Info

Product

Resources

About